May 21, 2008Expert Opinion on Investigational Drugs
Rivaroxaban, an oral direct factor Xa inhibitor
Population
Patients requiring prevention and treatment of venous and arterial thrombosis, including venous…
Comparison
Rivaroxaban (oral direct factor Xa inhibitor) vs Vitamin K antagonists (e.g., warfarin)
Design
Systematic_review
Authors
Discussion
Loading...
Member takes
Implication
Rivaroxaban may offer a convenient warfarin alternative for VTE; reinforces randomized evidence for direct Factor Xa inhibition.
Structured PICO
P
Population
Patients requiring prevention and treatment of venous and arterial thrombosis, including venous thromboembolism, pulmonary embolism, acute coronary syndromes, and non-valvular atrial fibrillation
I
Intervention
Rivaroxaban (oral direct factor Xa inhibitor)
C
Comparator
Vitamin K antagonists (e.g., warfarin)
Rivaroxaban is a promising oral direct Factor Xa inhibitor that may provide a much-needed alternative to warfarin for the prevention and treatment of various thromboembolic conditions.
Limitations
- Further data (especially large Phase III trials) are required
Cite This Study
Piccini et al. (2008) studied this question.